
|Articles|April 23, 2020
COVID-19: Sun Pharmaceuticals business update
Author(s)Mark Hagler
Advertisement
Mark Hagler, senior vice president, head of Ophthalmics, Oncology and LTC, at Sun Pharmaceuticals, shares a business update on how the company has responded and continued operations during the coronavirus pandemic.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
2
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
3
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5















































.png)


